StockNews.AI
GH
StockNews.AI
147 days

Guardant Health's Shield Blood Test Now Covered for VA Community Care Beneficiaries

1. Guardant Health’s Shield™ test is now covered for U.S. veterans. 2. Coverage includes no copayment for average-risk individuals aged 45 and older.

2m saved
Insight
Article

FAQ

Why Bullish?

The insurance coverage enhances market access, potentially increasing revenues. Historical precedents show reimbursement news often positively influences stock prices.

How important is it?

Expanded coverage signals approval and potential revenue growth, making it a key development. Short-term revenue impact predicted from increased test utilization.

Why Short Term?

Immediate effects on earnings expected as veterans utilize the screening. Similar past announcements have reflected quick stock movements.

Related Companies

VACMS
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA) as an in-network benefit, with no copay for average-risk individuals who are age 45 or older. Following Medicare.

Related News